Rigel Pharmaceuticals, Inc.
RIGL
$26.55
$0.602.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1,999.08% | 2,819.35% | 787.33% | 287.75% | 169.69% |
| Total Depreciation and Amortization | 8.39% | 26.13% | 51.81% | 89.85% | 79.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2,463.40% | -355.59% | -376.43% | -6.44% | 35.05% |
| Change in Net Operating Assets | -12,852.94% | -183.36% | 52.60% | -1,121.34% | -98.39% |
| Cash from Operations | 140.40% | 535.51% | 634.74% | 632.64% | 647.99% |
| Capital Expenditure | 100.00% | -280.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -47.06% | -25.76% | -25.76% | -62.16% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,370.53% | -1,069.06% | -1,437.31% | -38.91% | 189.29% |
| Cash from Investing | -2,336.44% | -1,053.70% | -1,380.18% | -41.46% | 196.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 312.47% | 573.91% | 202.03% | 107.48% | 87.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -123.06% | -149.81% | -416.91% |
| Cash from Financing | 105.16% | 152.60% | -104.96% | -164.53% | -163.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -167.23% | -149.39% | 236.46% | 237.39% | 187.74% |